duration of hospitalization – Page 2 – Communicable Diseases Research

Immature granulocytes: Innovative biomarker for SARS‑CoV‑2 infection

미성숙 과립구: SARS‑CoV‑2 감염에 대한 혁신적인 바이오마커

Article

Published on 2022-07-012022-09-11
Journal: Molecular medicine reports
[Category] COVID19(2023년), MERS, SARS, 바이오마커, 변종, 치료기술,

Molecular Epidemiology of AY.28 and AY.104 Delta Sub-lineages in Sri Lanka

스리랑카에서 AY.28 및 AY.104 델타 하위 계통의 분자 역학

Article

Published on 2022-06-212022-09-11
Journal: Frontiers in Public Health
[Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘,

[키워드] A222V absence Analysis analyzed AY.104 AY.28 B.1.617.2 characterized clinical disease clinical implication clinical implications COVID-19 Delta delta variant determine dominant variant duration of hospitalization Epidemiology expression expression level genomic Illumina individual Infection investigated Laboratory Lineage lineages Mutation no difference ORF1a ORF3 ORF3a ORF6 outbreak Oxford parental periscope Prevalence RNA SARS-CoV-2 SARS-CoV-2 genome SARS-CoV-2 genomes sequenced Seven severe disease severity sgRNA significantly higher Spike protein sub genomic RNA sub lineages. the spike protein variant
[DOI] 10.3389/fpubh.2022.873633 PMC 바로가기 [Article Type] Article

Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19

중증 COVID-19 환자 치료에서 토실리주맙과 메틸프레드니솔론의 효능 및 안전성 비교

Article

Published on 2022-06-012022-09-11
Journal: International immunopharmacology
[Category] COVID19(2023년), SARS, 바이오마커, 진단, 치료기술, 치료법,

[키워드] 28-day mortality 95% CI adverse event adverse events alternative caused clinical clinical response comparable COVID Cox regression analysis CRP Dexamethasone dose doses duration of hospitalization Efficacy and safety faster group groups hospitalized patient hospitalized patients ICU admission improvement intravenous methylprednisolone Methylprednisolone not significantly different occurred Other outcome oxygen oxygen saturation Patient Primary outcome problem prospective cohort study secondary Secondary outcomes severe COVID-19 Sleep disturbance Sleep disturbances statistically significant Tocilizumab tocilizumab. Treatment were recorded
[DOI] 10.1016/j.intimp.2022.108689 PMC 바로가기 [Article Type] Article

Opposing roles for sMAdCAM and IL-15 in COVID-19 associated cellular immune pathology

COVID-19 관련 세포 면역 병리학에서 sMAdCAM 및 IL-15의 반대 역할

Article

Published on 2022-06-012022-09-11
Journal: Journal of leukocyte biology
[Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] Activation Adhesion Molecule association Asymptomatic Asymptomatic cases CD4+ CD8 Cell cell adhesion molecule cellular characterized circulating Cohort correlated COVID COVID-19 COVID-19 pathology cytokine disease Disease progression duration of hospitalization dysfunction dysregulation effector memory ELISA evaluated Factors flow cytometry Frequency healthy control healthy controls homeostasis homeostatic hypoxemic IL-15 IL-6 IL-6 level IL-6 levels immune increase in India infected individuals Inflammatory factor inflammatory factors intermediate monocytes involved lymphocyte lymphopenia marker Mild moderate moderate to severe monocyte Monocytes mucosal multiparametric flow cytometry Mumbai Pathogenesis pathology plasma profiles quantified recruited regulatory T cells SARS-CoV-2 SARS-CoV-2 infected individual SARS-CoV-2 infected individuals severe disease sMAdCAM. Stage subset symptomatic individual symptomatic individuals symptomatic infection T cells was used while
[DOI] 10.1002/JLB.3COVBCR0621-300R PMC 바로가기 [Article Type] Article

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure

중증 호흡부전이 있는 COVID-19 환자의 구조 치료로서 흡입형 DNase, 바리시티닙 및 토실리주맙의 병용 투여

Article

Published on 2022-05-012022-09-12
Journal: Clinical immunology (Orlando, Fla.)
[Category] Coronavirus, COVID19(2023년), SARS, 바이오마커, 임상, 진단, 치료법,

Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial

Research

Published on 2022-04-252022-10-05
Journal: Nature Medicine
[Category] 임상,

Retinal Findings of Hospitalized Neonates Recovered from COVID-19 Infection: A Prospective, Observational, Descriptive Study

Observational Study

Published on 2022-04-052022-10-04
Journal: Journal of tropical pediatrics
[Category] COVID19(2023년), SARS, 임상,

Inflawell ® improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial

Inflawell®은 무작위 이중 맹검 위약 대조 임상 시험에서 중등도 COVID-19 환자의 호중구 대 림프구 비율을 개선하고 입원 기간을 단축합니다.

Randomized Controlled Trial

Published on 2022-04-012022-09-11
Journal: Inflammopharmacology
[Category] COVID19(2023년), SARS, 임상, 치료기술,

[키워드] activated activities addition administration Anti-inflammatory Anti-viral drugs average baseline Boswellia boswellic acids clinical clinical symptom Clinical symptoms clinical trial completion conducted cough COVID-19 COVID-19 symptom COVID-19 symptoms CRP Cytokines Disease progression double-blind duration of hospitalization dysfunction Dyspnea dysregulated immune response enrolled evaluated Fewer patients Gustatory headache help Hospital stay Hospitalization hospitalized patient IMPROVE increase in Inflammation Inflawell® syrup Intervention investigated LDH lymphocyte Lymphocytes marker Moderate COVID-19 moderate COVID-19 patients myalgia neutrophil Neutrophil-to-lymphocyte ratio Neutrophils NLR NLR. olfactory olfactory and gustatory dysfunction oxygen oxygen saturation Patient patients with moderate PCR-positive Placebo placebo group placebo-controlled placebo-controlled clinical trial Prevent prevent disease progression pro-inflammatory cytokines public health Randomized reduce Registered significant decrease significant increase significantly shorter Standard of care statistically significant Symptom syrup the placebo group the WHO therapeutic potential TNF Treatment Trial unique Vaccine
[DOI] 10.1007/s10787-022-00928-w PMC 바로가기 [Article Type] Randomized Controlled Trial

Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection

Observational Study

Published on 2022-03-112022-10-05
Journal: eLife
[Category] SARS, 임상,

[키워드] Adults adults hospitalized age age and sex amphiregulin Blood cell type cell types children with COVID-19 children with MIS-C contribute Control controls correlated correlations COVID-19 COVID-19 severity decrease determine disease disease tolerance duration of hospitalization Effect explain female females Follow-up greater homeostatic Hospitalization Hospitalized Human ILC ILCs immunology implicated increase independent Inflammation Innate innate lymphoid cell Innate lymphoid cells less lung lymphoid lymphoid cell lymphopenia male males marker Massachusett medicine. MIS-C morbidity and mortality mRNA Multiple NIH Outpatient pediatric phenotype produced Protein readiness recovering from COVID-19 SARS-CoV-2 SARS-COV-2 infection severe COVID-19 severity Sex subset supported systemic inflammation T cell subset T cells these cell tissue homeostasis Tolerance treated uninfected control was used with COVID-19
[DOI] 10.7554/eLife.74681 PMC 바로가기 [Article Type] Observational Study

Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II

Randomized Controlled Trial

Published on 2022-03-072022-10-04
Journal: Stem Cell Research & Therapy
[Category] MERS, SARS, 임상,

[키워드] 1:1 acute phase reactant Adverse adverse effect adverse event Allogeneic analyzed C-reactive protein caused CD4 CD8 chest imaging clinical symptom clinical trial control group COVID-19 Cytokine storm D-dimer declined demonstrated double-blind downregulation duration of hospitalization Efficacy Enrollment evaluate events ferritin FIVE GMP hospitalized patient hypoxia immune immune system increase in inflammatory lung disease injection intravenous infusion Intubated Laboratory parameters lymphocyte Lymphocyte count lymphopenia mechanism menstrual blood Menstrual blood stromal cells Mesenchymal stromal cell modulate MSCs New treatment outcomes Oxygen level Patient patients Phase I Placebo placebo-controlled clinical trial pulmonary involvement Randomized reduction Registered Result Safety safety endpoint SARS-CoV-2 Secretome severe COVID-19 Significant significantly stromal cell suppress survival rate survivor therapy treat treated Treatment treatment group Volume
[DOI] 10.1186/s13287-022-02771-w PMC 바로가기 [Article Type] Randomized Controlled Trial